Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and is headquartered in San Francisco, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer emerges as the lead suitor for the rare-disease company.

Why Global Blood Therapeutics Stock Is Vaulting Higher Today

Pfizer

The Wall Street Journal reports big pharma company Pfizer is looking to add sickle-cell disease drugmaker Global Blood Therapeutics to its pipeline.

Pfizer in advanced talks to buy Global Blood Therapeutics for about $5 billion

Rumors that Pfizer is in "advanced talks" to acquire Global Blood Therapeutics for about $5 billion sent GBT stock flying Friday. The post Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion appeared first on Investor's Business Daily.

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion

Pfizer is in talks to acquire Global Blood Therapeutics, which sells a treatment for sickle cell disease called Oxbryta, The Wall Street Journal reports.

Pfizer in Talks to Buy Global Blood Therapeutics: Report

Shares of Global Blood Therapeutics Inc. GBT, +48.47% jumped 9.5% in trading on Friday after The Wall Street Journal reported that Pfizer Inc. PFE, -0.49% is considering buying the company for about $5 billion. There were media reports earlier this week that Global Blood Therapeutics, which markets a sickle-cell treatment, is attracting takeover interest.

WSJ: Pfizer considering buying Global Blood Therapeutics for roughly $5 billion

Pfizer Inc is in advanced talks to buy drugmaker Global Blood Therapeutics for about $5 billion, the Wall Street Journal reported on Friday, citing people familiar with the matter.

Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ

Global Blood (GBT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Global Blood (GBT): Can Its 41.4% Jump Turn into More Strength?

A buyout rumor is powering the biotech's shares higher.

Why Global Blood Therapeutics Stock Is Soaring Today

Shares of Global Blood Therapeutics Inc. GBT, +3.04% were up 34.4% in premarket trading on Thursday after Bloomberg reported that the company is "attracting takeover interest," citing people familiar with the matter. Global Blood Therapeutics markets a treatment for sickle-cell disease called Oxbryta, which generated $194.7 million in revenue in 2021.

Global Blood Therapeutics shares jump 34% after Bloomberg report about 'takeover interest'

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on Wednesday, August 10, 2022, at 2:20 p.m. E.T.

GBT Announces Participation at the Wedbush PacGrow Healthcare Conference

Axcelis Technologies

Axsome Therapeutics

GoPro

Health Catalyst Inc

Skillz

Veru

Small-cap growth stocks with 1,000% upside potential is our topic for today. They are usually young companies with a market capitalization (cap) between $300 million and $2 billion.

7 Small-Cap Growth Stocks With 1,000% Upside Potential

Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Global Blood Therapeutics (GBT) Q2 Earnings Expected to Decline

Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell disease Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell disease

MHRA Grants Marketing Authorization for GBT's Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an expanded access program (EAP) for voxelotor in Brazil for the treatment of sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older who cannot satisfactorily be treated with a medicine authorized for use in Brazil. ANVISA, the Brazilian Health Regulatory Agency, has authorized the voxelotor EAP, which is actively enrolling at clinical sites around the country.

GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil

SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), has awarded grants of approximately $50,000 each to five community-based organizations (CBOs) as recipients of the inaugural Access to Care Empowerment for Sickle Cell (ACE) Grant Program. Through the ACE Grant Program, The GBT Foundation plans to fund up to $250,000 per year to support initiatives dedicated to advancing health equity and enhancing education, empowerment, and access to care for people living with sickle cell disease (SCD).

The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations

SOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2022, the compensation committee of GBT's board of directors granted 22 new employees options to purchase an aggregate of 10,600 shares of the company's common stock with a per share exercise price of $32.80 and restricted stock units for an aggregate 76,600 shares of the company's common stock. These awards were made under GBT's Amended and Restated 2017 Inducement Equity Plan (the Plan).

GBT Announces New Employment Inducement Grants

Global Blood Therapeutics (GBT) initiates the phase II portion of its planned phase II/III studies on pipeline candidate GBT601 to identify the optimal dose for the pivotal phase III portion of the trial

Global Blood (GBT) Initiates Phase II Study on SCD Candidate

Arrowhead Pharmaceuticals

Novavax

Regeneron Pharmaceuticals

Sanofi

Amid choppy markets, could there be potential in these top biotech stocks?

5 Top Biotech Stocks To Watch In July 2022

It started enrolling patients in a promising new clinical trial.

Why Global Blood Therapeutics Trended Upward Today

In the latest 1Q2022 earnings report, the lead medicine Oxbryta continues to generate highly aggressive growth. You can expect even stronger growth due to the recent Oxbryta launch for kids in the EU. There are also adult campaigns in other countries outside of the USA.

Global Blood Therapeutics: Powerhouse Of The Future

Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year

GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease

Biogen

CinCor Pharma

CRISPR Therapeutics

Emergent BioSolutions

Harmony Biosciences Holdings

Vigil Neuroscience

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first on InvestorPlace.

7 No-Brainer Biotech Stocks to Add to Your Buy List

The FDA bestows both orphan drug and rare pediatric disease designations to Global Blood's (GBT) inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease.

Global Blood's (GBT) Candidates for SCD Get Two FDA Tags

Grant proposals accepted through July 29, 2022 Grant proposals accepted through July 29, 2022

The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

News for Global Blood Therapeutics Stock (GBT)